CARA News and Press, Cara Therapeutics Inc. From 02/27/20

Cara Therapeutics (NASDAQ: CARA ): Q4 GAAP EPS of -$0.61 beats by $0.03 . Revenue of $4.5M (-18.6% Y/Y) misses by $0.89M . Press Release More news on: Cara Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

STAMFORD, Conn., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today an...

STAMFORD, Conn., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced th...

Two of the hottest places you can invest today are in biotech and cannabis. Cara Therapeutics (NASDAQ: CARA) will give you exposure to the former, while Scotts Miracle-Gro (NYSE: SMG) is a good option for investors looking to bank on the growth of the latter. Investors in both stocks ha...

The price of a stock doesn't really tell you much about it. A stock trading at $1,000 per share could be a bargain, while one trading at $2 per share could be expensive. To properly determine if a stock is trading at an attractive price, investors have to weigh a number of metrics, ranging from ...

With Canada and the U.S. dominating the cannabis industry , investors who are involved with marijuana stocks are waiting for another potential green rush. Right now the industries focus is on the U.S. and Canada. These are the two areas of the world with broad legislation and booming industri...

If you're looking for promising biotech stocks, there's plenty of options to choose from. Cara Therapeutics (NASDAQ: CARA) is a small-cap company that stayed strong for most of 2019 but has since given back a lot of its value. While it's fallen slightly out of favor, many experts still have ...

It's hard to forecast exactly how a specific stock will perform over just a 12-month period, let alone over five years. This is especially true for smaller biotech stocks , where there's an even greater degree of uncertainty due to the nature of the drug candidate development process. Cara Th...

An investment firm has launched its first marijuana exchange-traded fund (ETF) in Europe. The Medical Cannabis & Wellness UCITS ETF (XETRA: CBDX ) began its listing on Tuesday (January 14), and is available to investors on the Deutsche Boerse XETRA exchange based in Germany. The ne...

Today, we will be studying why Trevi Therapeutics ( TRVI ) is an attractive investment for 2020. Company overview Trevi Therapeutics is a clinical-stage company focused on the development of nalbuphine ER to treat multiple serious and chronic neurologically mediated conditions . Nalbuph...